This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Zejula (niraparib)
General Description:
Zejula (niraparib) is an oral targeted therapy used for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It works by inhibiting the PARP enzyme, which helps repair damaged DNA in cancer cells, thereby slowing tumor growth and improving clinical outcomes.
Zejula is administered orally as capsules, with dosage and treatment schedules tailored by a healthcare professional based on individual patient needs and tolerance.
Getting Zejula (niraparib) in India
Zejula is approved by multiple international regulatory agencies, including the FDA (U.S.), EMA (Europe), Health Canada, and TGA (Australia). While it may not yet be commercially available in India, patients can access it legally through a Named Patient Program (NPP) under the supervision of a licensed physician.
MitoGENE assists Indian patients in obtaining Zejula safely and efficiently, handling all regulatory approvals, import permits, and logistics to ensure a secure and compliant process.
Disease Indication:
• Gynaecological Cancer / Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Manufacturer:
Tesaro UK Limited
Usage:
Oral Capsules
Medicine Approved By:
• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Health Canada
• Therapeutic Goods Administration (TGA)
Available Dosage Form & Package:
• 100 mg capsules, 56 capsules per pack
• 100 mg capsules, 84 capsules per pack
Shipping:
Cold Chain Shipping
Zejula requires cold chain shipping to protect it from heat, light, and handling. Specialized medical couriers use temperature-controlled packaging and vehicles to maintain stability and effectiveness, ensuring the medicine remains safe and uncompromised during transit.
How to Access Zejula (niraparib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Zejula (niraparib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
